Home  /  Resource Library  /  Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Brutons Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events

Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Brutons Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events

Study investigated outcomes of patients with CLL treatment with BTK inhibitors.